公司资料
Halozyme Therapeutics, Inc. 股价、新闻与催化剂
- 股票代码:
- HALO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
103.00 USD (+4.40%)
收盘价
最后更新: 2026年8月17日
7.86B USD
市值
股价为何变动
As of Aug 17, 2026, HALO closed up 4.40% at $103.00. No new same-company headline was identified in the current news window.
公司概览
业务概览
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Halozyme is a U.S.-based specialty biotech company. It sits in platform-enabled drug delivery and oncology-adjacent therapeutics.
商业模式特征
The company generates value through royalty income, partner relationships, and technology licensing tied to subcutaneous formulation. Investors follow licensing growth, partner adoption, and whether the technology platform continues to expand across the industry.
生物医药行业定位
Halozyme occupies a unique position in biotech because it monetizes platform technology rather than relying only on its own clinical pipeline. That makes it less binary than many development-stage peers, but still catalyst-sensitive around deal flow and partner uptake.
未来催化剂
- Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal. The stock moves when royalty durability and partner breadth both keep expanding.
近期新闻
- 01
- 02
- 03
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。